Evidence map›Paper›PMID 41374974›Full record

ReviewCancers2025

Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM).

Apostolos Stathopoulos, Philippe Glorieux, Evangelos M Rokas, Huub F J Savelkoul

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Apostolos StathopoulosEpitopoietic Research Corporation, 5032 Gembloux Isnes, Belgium.ORCID 0000-0002-0406-6766
Philippe GlorieuxHematology-Oncology Department, Cliniques du Sud-Luxembourg, Vivalia, 6700 Arlon, Belgium.
Evangelos M RokasNeurosurgery Department, Athens Medical Center, 151 25 Athens, Greece.ORCID 0000-0002-1278-6384
Huub F J SavelkoulCell Biology and Immunology Group, Wageningen University and Research, 6700 AH Wageningen, The Netherlands.ORCID 0000-0001-6236-7092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) remains the most aggressive primary brain tumor, characterized by extensive intra-tumoral heterogeneity, profound local immunosuppression, and a highly adaptive tumor microenvironment that resists conventional therapies. Immunotherapy for GBM tries to overcome these barriers by reactivating anti-tumor immunity through cellular, molecular, and immune-modulatory interventions. The therapeutic efficacy of the cell-based vaccines in patients with glioma and glioblastoma is primarily driven by tumor antigen-specific CD8

Indexed as

allogeneic CTLcancer transplant immune recognition therapy (CTIRT)GBM vaccineimmunotherapyrecurrent glioblastoma

Identifiers

PMID41374974
PMCPMC12691356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.